Role of biomarkers in cardioncology

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 12, 2011, Pages 1937-1948

  Cardinale, Daniela ^a   Salvatici, Michela ^a   Sandri, Maria T ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Biomarkers; Cardioncology; Cardiotoxicity; Chemotherapy; Left ventricular dysfunction

Indexed keywords

AMINO TERMINAL PRO ATRIAL NATRIURETIC PEPTIDE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENALAPRIL; FATTY ACID BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LAPATINIB; NATRIURETIC FACTOR; PEPTIDE HORMONE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAZOXANE; SORAFENIB; SUNITINIB; TISSUE PLASMINOGEN ACTIVATOR; TRASTUZUMAB; TROPONIN; TROPONIN I; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ACUTE LYMPHOBLASTIC LEUKEMIA; BLUNT TRAUMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DNA DAMAGE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; EVIDENCE BASED MEDICINE; GENE EXPRESSION; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; INFLAMMATION; KIDNEY FAILURE; LEUKEMIA; LONG TERM CARE; LUNG EMBOLISM; MINIMALLY INVASIVE PROCEDURE; MORTALITY; MULTIPLE CYCLE TREATMENT; NEOPLASM; OBESITY; ONCOLOGY; OVERALL SURVIVAL; PATIENT MONITORING; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT PROLONGATION; QUALITY OF LIFE; REVIEW; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SEPSIS; STROKE;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; NATRIURETIC PEPTIDES; NEOPLASMS; TROPONIN;

EID: 84856534493     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.692     Document Type: Review

References (105)

1. Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, et al. Clinical cancer advances 2005: Major research advances in cancer treatment, prevention, and screening. A report from the American society of clinical oncology. J Clin Oncol 2006;24:190-205. (Pubitemid 46630512)
2. Kesteloot H, Sans S, Kromhout D. Dynamic of cardiovascular and all-cause mortality in western and eastern Europe between 1970 and 2000. Eur Heart J 2006;27:107-13. (Pubitemid 41785939)
3. Donfrancesco C, Lo Noce C, Brignoli O, Riccardi G, Ciccarelli P, Dima F, et al. Italian network for obesity and cardiovascular disease surveillance: A pilot project. BMC Fam Pract 2008;9:53.
4. Reicher-Reiss H, Jonas M, Goldbourt U, Boyko V, Modan B. Selectively increased risk of cancer in men with coronary heart disease. Am J Cardiol 2001;87:459-62. (Pubitemid 32150010)
5. Kuller LH, Matthews KA, Meilahn EN. Estrogen and women's health: Interrelation of coronary heart disease, breast cancer and osteoporosis. J Steroid Biochem Mol Biol 2000;74:297-309. (Pubitemid 32126242)
6. Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, et al. American society of clinical oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects. J Clin Oncol 2007;25: 3991-4008. (Pubitemid 47477279)
7. Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin AJ, Rychik J, et al. Enalapril to prevent cardiac function decline in longterm survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004;22:820-8. (Pubitemid 41103593)
8. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al. Recent cancer survival in Europe: A 2000-2002 period analysis of EUROCARE-4 data. Lancet Oncol 2007;8:784-9.
9. Yeh ET. Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med 2006;57:485-98. (Pubitemid 43262003)
10. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, et al. Overall survival and causespecific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol 2007;25:4952-60. (Pubitemid 350220427)
11. Mertens A, Liu Q, Neglia J, Wasilewski K, Leisenring W, Armstrong GT, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: The childhood cancer survivor study. J Natl Cancer Inst 2008;100:1368-79.
12. Cardinale D. A new frontier: Cardioncology. Cardiologia 1996; 41:887-91.
13. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010;102:14-25.
14. Zambelli A, Porta MD, Rosti V. From cancer patients to cancer survivors:the issue fof cardioncology-a biological perspective. Eur J Cancer 2010;46:697-702.
15. Minotti G, Salvatorelli E, Menna P. Pharmacological foundations of cardio-oncology. J Phamracol Exp Ther 2010;334:2-8.
16. Lenihan DJ, Cardinale D, Cipolla CM. The compelling need for a cardiology and oncology partnership and the birth of the international cardioncology society. Progr Cardiovasc Dis 2010;334:2-8.
17. Hong RA, Limura T, Sumida KN, Eager RM. Cardio-oncology/ onco-cardiology. Clin Cardiol 2010;33:733-7.
18. Yeh ETH, Bickford C. Cardiovascular complications of cancer therapy. J Am Coll Cardiol 2009;53:2231-47.
19. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE Anthracycline-induced cardiotoxicity: Course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007;8:1039-58. (Pubitemid 46929299)
20. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf 2008;31:459-67. Review. (Pubitemid 351695459)
21. Bonow RO, Bennett S, Casey DE Jr, Ganiats TG, Hlatky MA, Konstam MA, et al. ACC/AHA clinical performance measures for adults with chronic heart failure: A report of the American college of cardiology/American heart association task force on performance measures (writing committee to develop heart failure clinical performance measures): Endorsed by the heart failure society of America. Circulation 2005;112:1853-87. (Pubitemid 41368160)
22. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077-84. (Pubitemid 30207690)
23. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7. (Pubitemid 10218041)
24. Haq MM, Legha SS, Choksi J, Hortobagyi GN, Benjamin RS, Ewer M, et al. Doxorubicin-induced congestive heart failure in adults. Cancer 1985;56:1361-5. (Pubitemid 15230583)
25. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy. Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213-20.
26. Robison LL, Green DM, Hudson M, Meadows AT, Mertens AC, Packer RJ, et al. Long-term outcomes of adult survivors of childhood cancer. Cancer 2005;104(Suppl 11):2557-64.
27. Doyle JJ, Neugut AI, Jacobson JS. Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. Clin Oncol 2005;23:8597-605. (Pubitemid 46211501)
28. Meinardi MT, Gietema JA, van Veldhuisen DJ, van der Graaf WT, de Vries EG, Sleijfer DT. Long-term chemotherapy-related cardiovascular morbidity. Cancer Treat Rev 2000;26:429-47. (Pubitemid 32094861)
29. van den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink WW, Rodrigus PT, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006;24:467-75. (Pubitemid 46630466)
30. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR, et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007;50:1435-41. (Pubitemid 47494586)
31. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the cardiology committee of the children cancer study group. Pediatrics 1992;89:942-9.
32. Meinardi MT, van der Graaf WT, van Veldhuisen DJ, Gietema JA, de Vries EG, Sleijfer DT. Detection of anthracyclineinduced cardiotoxicity. Cancer Treat Rev 1999;25:237-47.
33. Wells QS, Lenihan D. Reversibility of left ventricular dysfunction resulting from chemotherapy: Can this be expected? Progr Cardiovasc Dis 2010;53:140-8.
34. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. A report of the American college of cardiology foundation/American heart association task force on practice guidelines developed in collaboration with the international society for heart and lung transplantation. J Am Coll Cardiol 2009;53:e1-e90.
35. Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: Strategies for early detection. Lancet Onocl 2009;10:391-9.
36. Healey Bird BRJ, Swain SM. Cardiac toxicity in breast cancer survivors: Review of potential cardiac problems. Clin Cancer Res 2008;14:14-24. (Pubitemid 351377973)
37. Nielsen D, Jensen JB, Dombernowsky P, Munck O, Fogh J, Brynjolf I, et al. Epirubicin cardiotoxicity: A study of 135 patients with advanced breast cancer. J Clin Oncol 1990;8: 1806-10. (Pubitemid 20382342)
38. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, longterm observational study of outcome in 120 patients. Ann Oncol 2002;13:699-709. (Pubitemid 34567375)
39. O'Brien PJ. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology 2008;245:206-18.
40. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined-a consensus document of the Joint European society of cardiology/American college of cardiology committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
41. Panteghini M. Role and importance of biochemical markers in clinical cardiology. Eur Heart J 2004;25:1187-96. (Pubitemid 38891568)
42. Jensen JK, Atar D, Mickley H. Mechanism of troponin elevations in patients with acute ischemic stroke. Am J Cardiol 2007,15:867-70. (Pubitemid 46365612)
43. Adamcova M, Sterba M, Simunek T, Potacova A, Popelova O, Mazurova Y, et al. Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opin Drug Saf 2005;4:457-72. (Pubitemid 40723720)
44. Sparano JA, Brown DL, Wolff AC. Predicting cancer therapyinduced cardiotoxicity. The role of troponins and other markers. Drug Safety 2002;25:301-11. (Pubitemid 34634269)
45. Expert working group on biomarkers of drug-induced cardiac toxicity report to the non-clinical studies subcommittee of the advisory committee for pharmaceutical science, 2002. http://www. fda.gov/ohrms/dockets/ac/02/briefing/ 3891B101Troponin. Outline. pdf NICE website press release.
46. Adamcova M, Simunek T, Kaiserova H, Popelova O, Sterba M, Potacova A, et al. In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. Toxicology 2007;237:218-28. (Pubitemid 47031418)
47. Urbanova D, Urban L, Carter A, Maasova D, Mladosievicova B. Cardiac troponins-biochemical markers of cardiac toxicity after cytostatic therapy. Neoplasma 2006;53:183-90. (Pubitemid 43844375)
48. Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997,96: 2641-8.
49. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: Long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010;11:950-61.
50. Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000;36:517-22.
51. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of Troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749-54. (Pubitemid 38737923)
52. Cardinale D, Sandri MT, Martinoni A, Borghini E, Civelli M, Lamantia G, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002;13:710-5. (Pubitemid 34567376)
53. Auner HW, Tinchon C, Linkesch W, Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003;82:218-22. (Pubitemid 36701012)
54. Specchia G, Buquicchio C, Pansini N, Di Serio F, Liso V, Pastore D, et al. Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med 2005;145:212-20. (Pubitemid 40692404)
55. Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S, et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 2005;16:798-804. (Pubitemid 40767103)
56. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: Clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010;28:3910-6.
57. Morris PG, Chen C, Steingart RM, Fleisher M, Lin NU, Moy B, et al. Troponin I and C-Reactive Protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res. 2011;17:3490-9.
58. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26:5204-12.
59. Christenson RH, Phillips D. Sensitive and high sensitivity next generation cardiac troponin assays: More than just a name. Pathology 2011;43:213-9.
60. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, et al. Early detection and predictor of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011;107:1375-80.
61. Adams JE 3rd, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990? Circulation 1993;88:750-63. Review. (Pubitemid 23228075)
62. Germanakis I, Anagnostatou N, Kalmanti M. Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity. Pediatr Blood Cancer 2008;51:327-33.
63. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474-81. (Pubitemid 44901520)
64. Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: Systematic review of the literature and recommendations for use. Am J Clin Pathol 2008;130:688-95.
65. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracyclines-induced myocardial damage: A review of the most promising strategies. Br J Haematol 2005;131:561-78. (Pubitemid 43899624)
66. Nakamae H, Tsumura K, Terada Y, Nakane T, Nakamae M, Ohta K, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 2005;104:2492-8. (Pubitemid 41691573)
67. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004;351:145-53. (Pubitemid 38886649)
68. Packer M. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
69. Goetze JP. Biochemistry of pro-B-type natriuretic peptidederived peptides: The endocrine heart revisited. Clin Chem 2004;50:1503-10. (Pubitemid 39121217)
70. Struthers AD. Ten years of natriuretic peptide research: A new dawn for their diagnostic and therapeutic use? Br Med J 1994;308:1615-9. (Pubitemid 24181873)
71. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 2003;24:341-56. (Pubitemid 36724374)
72. Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: A marker predictive of cardiac dysfunction? Clin Chem 2005;51:1405-10. (Pubitemid 41060872)
73. Erkus B, Demirtas S, Yarpuzlu AA, Can M, Genc Y, Karaca L. Early predicyion of anthracycline induced cardiotoxicity. Acta Pedriatr 2007;96:506-9. (Pubitemid 46466109)
74. Zver S, Zadnik V, Cernelc P, Kozelj M. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int J Hematol 2008;88:227-36.
75. Feola M, Garrone O, Occelli M, Francini A, Biggi A, Visconti G, et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: Effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 2011; 148:194-8.
76. Lee HS, Son CB, Shin SH, Kim YS. Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity. Cancer Res Treat 2008;40:121-6.
77. Urbanova D, Urban L, Simkova I, Danova K, Mikuskova E, Mladosievicova B. Long-term cardiac effects of treatment for childhood leukemia. Neoplasma 2010;57:179-83.
78. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the childhood cancer survivor study cohort. Br Med J 2009;339:b4606.
79. Dodos F, Halbsguth T, Erdmann E, Hoppe UC. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 2008;97:318-26. (Pubitemid 351725058)
80. Ekstein S, Nir A, Rein AJ, Perles Z, Bar-Oz B, Salpeter L, et al. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children. J Pediatr Hematol Oncol 2007;29:440-4. (Pubitemid 47026244)
81. Cardinale D, Sandri MT. Role of biomarkers in chemotherapyinduced cardiotoxicity. Prog Cardiovasc Dis 2010;53:121-9. Review.
82. Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006;24:2276-82. (Pubitemid 46630657)
83. Knobloch K, Tepe J, Lichtinghagen R, Luck HJ, Vogt PM. Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab. Int J Cardiol 2008;125:113-5. (Pubitemid 351305407)
84. Wu AH. Plasma BNP/NT-proBNP assays: What do they target and what else might they recognize? Heart Fail Clin 2006;2: 291-8. Review. (Pubitemid 44716759)
85. Prontera C, Zaninotto M, Giovannini S, Zucchelli GC, Pilo A, Sciacovelli L, et al. Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: The CardioOrmocheck study. Clin Chem Lab Med 2009;47:762-8.
86. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Biochemical diagnosis of impaired left ventricular ejection fraction-comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP). Clin Chem Lab Med 2004;42:159-63. (Pubitemid 38401442)
87. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: Systematic review. Br Med J 2005;330:625.
88. Takeda Y, Takeda Y, Fukutomi T, Suzuki S, Yamamoto K, Ogata M, et al. Effects of carvedilol on plasma B-type natriu-retic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol 2004;94: 448-53. (Pubitemid 39127468)
89. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004;110:2168-74. (Pubitemid 39372496)
90. Clerico A, Carlo Zucchelli G, Pilo A, Passino C, Emdin M. Clinical relevance of biological variation: The lesson of brain natriuretic peptide (BNP) and (NT-proBNP) assay. Clin Chem Lab Med 2006;44:366-78. Review.
91. Morrow DA, de Lemos JA, Blazing MA, Sabatine MS, Murphy SA, Jarolim P, et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 2005;294:2866-71. (Pubitemid 41785867)
92. Nuver J, Smit AJ, Sleijfer DT, van Gessel AI, van Roon AM, van der Meer J, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004;40:701-6. (Pubitemid 38326620)
93. Vaughn DJ, Palmer SC, Carver JR, Jacobs LA, Mohler ER. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008;112:1949-53. (Pubitemid 351574070)
94. Nuver J, De Haas EC, Van Zweeden M, Gietema J, Mejer C. Vascular damage in testicular cancer patients: A study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep 2010;23:247-53.
95. Kilcullen N, Viswanathan K, Das R, Morrell C, Farrin A, Barth JH, et al. Heart-type fatty acid-binding protein predicts longterm mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values. J Am Coll Cardiol 2007;50:2061-7. (Pubitemid 350087577)
96. O'Donoghue M, de Lemos JA, Morrow DA, Murphy SA, Buros JL, Cannon CP, et al. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation 2006;114:550-7. (Pubitemid 44199644)
97. Glatz JFC, van der Voort D, Hermens WT. Fatty acid-binding protein as the earliest available plasma marker of acute myocardial injury. J Clin Ligand Assay 2002;25:167-77. (Pubitemid 36748968)
98. Tanaka T, Hirota Y, Sohmiya K, Nishimura S, Kawamura K. Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction. Clin Biochem 1991;24:195-201.
99. Peetz D, Post F, Schinzel H, Schweigert R, Schollmayer C, Steinbach K, et al. Glycogen phosphorylase BB in acute coronary syndromes. Clin Chem Lab Med 2005;43:1351-8.
100. ElGhandour AH, El Sorady M, Azab S, ElRahman M. Human heart-type fatty acid-binding protein as an early diagnostic marker of doxorubicin cardiac toxicity. Hematol Rev 2009; e1-e6.
101. Horacek JM, Vasatova M, Tichy M, Pudil R, Jebavy L, Maly J. The use of cardiac biomarkers in detection of cardioxicity associated with conventional and high-dose chemotherapy for acute leukemia. Exp Oncol 2010;32:97-9.
102. Hogye M, Mandi Y, Csanady M, Sepp R, Buzás K. Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. Am J Cardiol 2004;94:249-51. (Pubitemid 38902885)
103. Mercuro G, Cadeddu C, Piras A, Dessí M, Madeddu C, Deidda M, et al. Early epirubicin-induced myocardial dysfunction revealed by serial tissue doppler echocardiography: Correlation with inflammatory and oxidative stress markers. Oncologist 2007;12:1124-33. (Pubitemid 350007024)
104. Cadeddu C, Piras A, Mantovani G, Deidda M, Dessí M, Madeddu C, et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 2010;160:487.e1-e7.
105. Ederhy S, Massard C, Dufaitre G, Balheda R, Meuleman C, Rocca CG, et al. Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase 1 trials. Invest New Drugs DOI 10.1007/s10637-010-9546-8.